

## DAFTAR PUSTAKA

1. Rashedi R, Samieefar N, Akhlaghdoust M, Mashhadi M, Darzi P, Rezaei N. Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics. *Acta Biomed.* 2022;14;93(1):2-11
2. Gunadi, Hakim MS, Wibawa H, Marcellus, Setiawaty V, Slamet, et al. Is the Infection of the SARS-CoV-2 Delta Variant Associated With the Outcomes of COVID-19 Patients? *Front Med (Lausanne).* 2021;9(2);1-8.
3. American Medical Association. News From the Centers for Disease Control and Prevention. *JAMA.* 2021;326(22):225-35
4. Zayet S, Gendrin V, Gay C, Selles P, Klopfenstein T. Increased COVID-19 Severity among Pregnant Patients Infected with SARS-CoV-2 Delta Variant, France. *Emerg Infect Dis.* 2022;28(5):1048–50.
5. Sekihara K, Shibasaki T, Okamoto T, Matsumoto C, Ito K, Fujimoto K, et al. Poor prognosis of patients with severe COVID-19 admitted to an infectious disease intensive care unit during the pandemic caused by the Delta variant in Japan. *Glob Health Med.* 2022;30;4(2):2-15
6. Kementerian Kesehatan Republik Indonesia. *Info Infeksi Emerging Kesehatan RI.* Jakarta; 2021.
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395:497–06.
8. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med.* 2020;180:1345–55.
9. Burhan E, Isbaniah F, Susanto AD, Aditama TY, Soedarsono, Sartono TR, et al. *Pneumonia COVID-19 : Diagnosis dan Penatalaksanaan di Indonesia.* Jakarta: Perhimpunan Dokter Paru Indonesia; 2020.h2-24.

10. University of Michigan. Inpatient guidance for guidance for diagnosis and treatment of COVID-19 in adults and children. 2020;(2);p21-46
11. Public Health Ontario. Prevalence and Predictors of Antibiotic Prescribing in Patients with COVID-19 – What We Know So Far. Ontario. 2020;p20-92
12. Daria S, Islam MdR. Indiscriminate Use of Antibiotics for COVID-19 Treatment in South Asian Countries is a Threat for Future Pandemics Due to Antibiotic Resistance. *Clinical Pathology*. 2022;18;15:263-80
13. Centers for Disease Control and Prevention. COVID-19 U.S Impact on Antimicrobial Resistance . CDC. 2022;21-46
14. Langford BJ, So M, Simeonova M, Leung V, Lo J, Kan T, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. *Lancet Microbe*. 2023;4(3):p179–91.
15. Sulayyim HJ Al, Ismail R, Hamid A Al, Ghafar NA. Antibiotic Resistance during COVID-19: A Systematic Review. *Int J Environ Res Public Health*. 2022;19:(9):1-7
16. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. *BMC Infect Dis*. 2020 ;20(1):1–7.
17. Vijey S, Bansal N, Rao B K, Vaeraraghavan B, Rodrigues C, Wattal C, et al. Secondary Infection in Hospitalized COVID-19 Patients : Indian Experience. *National Library of Medicine*. 2021;14:1893–903
18. Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G, et al. Bloodstream infections in critically ill patients with COVID-19. *Eur J Clin Invest*. 2020;50:p133-49
19. Patrier J, Timsit JF. Carbapenem use in critically ill patients. *Curr Opin Infect Dis*. 2020;33(1):86–91.
20. Lau CL, Periyasamy P, Saud MN, Robert SA, Gan LY, Chin SY, et al. Plethora of Antibiotics Usage and Evaluation of Carbapenem Prescribing Pattern in Intensive Care Units: A Single-Center

Experience of Malaysian Academic Hospital. *Antibiotics*. 2022;30;11(9):1172-89

21. Millenia A N. Penilaian Rasionalitas Penggunaan Antibiotik pada Pasien Pneumonia dengan COVID019 menggunakan Metode Gyssens di Rumah Sakit Umum Pusat Dr. Sardjito Yogyakarta. Vol. 2. *Univeristas Islam Indonesia*; 2022;(2);1–50.
22. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. 2022;399(10325):p629–55.
23. Pinte L, Ceasovschi A, Niculae CM, Stoichitoiu LE, Ionescu RA, Balea MI, et al. Antibiotic Prescription and In-Hospital Mortality in COVID-19: A Prospective Multicentre Cohort Study. *J Pers Med*. 2022;26;12(6):877-92
24. Kementerian Kesehatan Republik Indonesia. Info Infeksi Emerging Kementerian Kesehatan RI. Kementerian Kesehatan RI . 2020.
25. Sloan CE, Bernard S, Nachamkin I. Appropriateness of expectorated sputum cultures in the hospital setting. *Diagn Microbiol Infect Dis*. 2015 Sep;83(1):74–6.
26. MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza (H1N1). *BMC Infect Dis*. 2018 Dec 7;18(1):637-65
27. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020 Feb;395(10223):507–13.
28. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. *Clinical Microbiology and Infection*. 2021 Jan;27(1):61–6.

29. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clinical Microbiology and Infection*. 2020 Apr;26(12):1622–9.
30. Zahariadis G, Gooley TA, Ryall P, Hutchinson C, Latchford MI, Fearon MA, et al. Risk of Ruling out Severe Acute Respiratory Syndrome by Ruling in another Diagnosis: Variable Incidence of Atypical Bacteria Coinfection Based on Diagnostic Assays. *Can Respir J*. 2006;13(1):17–22.
31. National Collaborating Centre for Infectious Diseases. *Insight Public Health*. 2020;23-72
32. Council of Canadian Academies. *When Antibiotics Fail*. CAC. Ottawa; 2019; p12-92
33. Oliva J, Terrier O. Viral and Bacterial Co-Infections in the Lungs: Dangerous Liaisons. *Viruses*. 2021 Aug 30;13(9):1725-32
34. Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, et al. Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. *Sci Rep*. 2019;7;9(1):2-8
35. Centers for Disease Control and Prevention. *National Infection & Death Estimates*. CDC. 2021;48-58
36. Pizzorno A, Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, et al. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. *Front Immunol*. 2019;29;10-32
37. Lu X, Tumpey T M, Morken T, Zaki S R, Cox N, Katz J. Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated for Humans. *J Viral*. 2019;73:5903–11.
38. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients

hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. *Antimicrob Resist Infect Control*. 2020;22;9(1):1–7.

39. Tiri B, Sensi E, Marsiliani V, Cantarini M, Priante G, Vernelli C, et al. Antimicrobial Stewardship Program, COVID-19, and Infection Control: Spread of Carbapenem-Resistant *Klebsiella Pneumoniae* Colonization in ICU COVID-19 Patients. What Did Not Work? *Journal of Clinical Medicine* 2020;9(9):2744-60
40. Gomez-Simmonds A, Annavajhala MK, McConville TH, Dietz DE, Shoucri SM, Laracy JC, et al. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. *Journal of Antimicrobial Chemotherapy*. 2021;76(2):380–4.
41. Despotovic A, Milosevic B, Cirkovic A, Vujovic A, Cucanic K, Cucanic T, et al. The impact of covid-19 on the profile of hospital-acquired infections in adult intensive care units. *Antibiotics*. 2021;10(10):1146-62
42. Pourajam S, Kalantari E, Talebzadeh H, Mellali H, Sami R, Soltaninejad F, et al. Secondary Bacterial Infection and Clinical Characteristics in Patients With COVID-19 Admitted to Two Intensive Care Units of an Academic Hospital in Iran During the First Wave of the Pandemic. *Front Cell Infect Microbiol*. 2022;23;12:141-52
43. Sang L, Xi Y, Lin Z, Pan Y, Song B, Li C an, et al. Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study. *Ann Palliat Med*. 2021;10(8):855-72
44. Meawed TE, Ahmed SM, Mowafy SMS, Samir GM, Anis RH. Bacterial and fungal ventilator associated pneumonia in critically ill COVID-19 patients during the second wave. *J Infect Public Health*. 2021;14(10):1375–80.
45. Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. *Science* (1979). 2020;7;369(6504):712–7.

46. National institute of health. COVID-19 Treatment Guidelines. 2020;41-62
47. Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. *Clinical Microbiology and Infection*. 2021;27(3):451–7.
48. Miranda C, Silva V, Capita R, Alonso-Calleja C, Igrejas G, Poeta P. Implications of antibiotics use during the COVID-19 pandemic: present and future. *Journal of Antimicrobial Chemotherapy*. 2020;1;75(12):3413–6.
49. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020 Mar 12;579(7798):270–3.
50. Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2021 Tentang Pedoman Penggunaan Antibiotik. 2021.h10-48
51. Panduan Penatagunaan Antimikroba di Rumah Sakit. Edisi 1. Direktorat Pelayanan Kesehatan Rujukan dan Direktorat Jenderal Pelayanan Kesehatan Kementerian Kesehatan RI. 2021;h20-4
52. Peraturan menteri kesehatan republik indonesia nomor 8 tahun 2015. h4-22
53. Ramadhanti S, Radji M, Andalusia L R, Soetikno V, Supardi S. Evaluasi Kualitatif Penggunaan Antibiotik pada Pasien Ventilated Associated Pneumonia (VAP) dengan metode Gyssens di ruang ICU RS Kanker Dharmais Jakarta. *FMIPAUI*. 2018;15:1–68.
54. Dhillon J, Agustin H, Burhan E, Tedja I, Syahrudin S, Ratnawati, et al. Evaluasi Penggunaan Antibiotik dengan Metode Gyssens dan Hubungannya dengan Luaran Pasien Pneumonia Komunitas yang Dirawat Inap di Rumah Sakit Umum Pusat Persahabatan. Jakarta. Library UI. Fakultas Kedokteran Universitas Indonesia; 2020;8:h1–74.

55. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) Revisi Ke-4. Vol. 76, Kementerian Kesehatan RI. 2020. h5–16.
56. Natadidjaja, R.I (2020). Konsep *RASPRO* : Metode Tataguna Antibiotik Bijak dalam Rangka Menjalankan Fungsi PPRA di Rumah Sakit. *Journal of Hospital Accreditation*. Jakarta. 2020;4;02:57-62
57. Bardi T, Pintado V, Gomez R M, Escudero R, Azzam A, Diez Y et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. *Eur J Clin Microbiol Infect Dis*. 2021;40(3):495–502.
58. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA*. 2020;323:1574–81.
59. Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: A cross-sectional study. *Crit Care*. 2020;24(1):1–10.
60. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020 May 1;8(5):475–81.
61. Feng H, Gan CCR, Leiva D, Zhang BL, Davies SE. COVID-19, sex, and gender in China: a scoping review. *Global Health*. 2022;18(1):1–12.
62. Malmgren J, Guo B, Kaplan HG. Continued proportional age shift of confirmed positive COVID-19 incidence over time to children and young adults: Washington State March - August 2020. *PLoS One*. 2021;16:52
63. Sunartejo B, Fitriani C, Kurniawaty juni. Hubungan antara kesesuaian terapi antibiotik empiris dengan hasil uji kepekaan kuman terhadap

angka kematian pada pasien sepsis di ICU RSUP Dr. Sardjito Yogyakarta. Repository Universitas Gadjah Mada. 2019;1–13.

64. Gong J, Dong H, Xia QS, Huang Z yi, Wang D kun, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. *BMC Infect Dis.* 2020;1;20(1).22-78
65. Van Goethem N, Chung PYJ, Meurisse M, Vandromme M, De Mot L, Brondeel R, et al. Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021–2022. *Viruses.* 2022 Jun 1;14(6).11-76
66. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet.* 2022 Apr 2;399(10332):1303–12.
67. World Health Organization. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection. Geneva. 2022;p234-90
68. Bordallo B, Bellas M, Fernandes Cortez A, Vieira M, Pinheiro M. Severe COVID-19: what have we learned with the immunopathogenesis. 2023.1(4);34-72
69. Tanase DM, Gosav EM, Radu S, Ouatu A, Rezus C, Ciocoiu M, et al. Review Article Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? 2019;14;50-72
70. Abumayyaleh M, Nuñez-Gil IJ, El-Battrawy I, Estrada V, Becerra-Muñoz VM, Uribarri A, et al. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. *Front Med (Lausanne).* 2021;14;8:1742-82

71. Morbidity and Mortality Weekly Report.CDC. 2023. <https://www.cdc.gov/mmwr/index2023.html>
72. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020 Mar 28;395(10229):1054–62.
73. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA - Journal of the American Medical Association*. 2020 May 26;323(20):2052–9.
74. Calderón-Parra J, Muiño-Míguez A, Bendala-Estrada AD, Ramos-Martínez A, Muñoz-Rubio E, Carracedo EF, et al. Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. *PLoS One*. 2021 May 1;16:p120-72
75. Liu C, Wen Y, Wan W, Lei J, Jiang X. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. *Int Immunopharmacol*. 2021 Jan 1;90;3-18
76. Taxifulati Y, Wushouer H, Fu M, Zhou Y, Du K, Zhang X, et al. Antibiotic use and irrational antibiotic prescriptions in 66 primary healthcare institutions in Beijing City, China, 2015–2018. *BMC Health Serv Res*. 2021 Dec 1;21(1);2-32
77. Kamara IF, Kumar AMV, Maruta A, Fofanah BD, Njuguna CK, Shongwe S, et al. Antibiotic Use in Suspected and Confirmed COVID-19 Patients Admitted to Health Facilities in Sierra Leone in 2020–2021: Practice Does Not Follow Policy. *Int J Environ Res Public Health*. 2022 Apr 1;19(7);12-42
78. Kristanti W, Yulia R, Herawati F. Analysis of Antibiotic Use in COVID-19 Patients at a Hospital in Sidoarjo. *Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia*. 2022 Aug 31;9(2):200–8.

79. Martin AJ, Shulder S, Dobrzynski D, Quartuccio K, Pillinger KE. Antibiotic Use and Associated Risk Factors for Antibiotic Prescribing in COVID-19 Hospitalized Patients. *J Pharm Pract.* 2021 Apr 1;(2);2- 19
80. Lau CL, Periyasamy P, Saud MN, Robert SA, Gan LY, Chin SY, et al. Plethora of Antibiotics Usage and Evaluation of Carbapenem Prescribing Pattern in Intensive Care Units: A Single-Center Experience of Malaysian Academic Hospital. *Antibiotics.* 2022 Apr;11(9):1172-80
81. Stoichitoiu LE, Pinte L, Ceasovschiu A, Cernat RC, Vlad ND, Padureanu V, et al. In- Hospital Antibiotic Use for COVID- 19: Facts and Rationales Assessed through a Mixed- Methods Study. *J Clin Med.* 2022;11;3-13
82. Yusuf muhammad, Auliah N, Evangelista H. Evaluasi Penggunaan Antibiotik dengan Metode Gyssens pada Pasien Pneumonia di Rumah Sakit Bhayangkara Kupang. *jurnal riset kefarmasian indonesia.* 2019;(1);4-30
83. Masyrifah M, Andrajati R, Triana L Y. Qualitative Evaluation of Antibiotics Use with Gyssens Method in Sepsis Patients at Fatmawati Central General Hospita Jakarta. 2022;9(2):67–80.
84. Adani SD, Zulfariansyah A, Santoso PTR. Quality Assesment of Antibiotic Prescription for Sepsis Treatment in Intensive Care Unit at Top Referral Hospital in West Java, Indonesia. *Althea Medical Journal.* 2017 Jun;4(2):286–92.
85. Dewi RS, Radji M, Andalusia R. Evaluation of antibiotic use among sepsis patients in an intensive care unit: A cross-sectional study at a referral hospital in Indonesia. *Sultan Qaboos Univ Med J [Internet].* 2018;18(3):367–73.
86. Zhang J jin, Dong X, Liu G hui, Gao Y dong. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. *Clin Rev Allergy Immunol.* 2023;1;12;14-40